Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma

NCT04698213 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

75

Enrollment

OTHER

Sponsor class

Conditions

Renal Carcinoma Metastatic

Interventions

DRUG: Axitinib Oral Tablet
DRUG: Avelumab

Sponsor

Consorzio Oncotech

Collaborators

[object Object]